The international Low Grade Glioma Registry is the world’s largest and longest-running study of people with astrocytoma and oligodendroglioma brain tumors. We aim to discover why some people develop low grade glioma brain tumors while other people do not, and learn more about the effects treatments have on the daily life of patients and their care partners. The Registry is actively recruiting participants from around the world who are age 21 and older.

Recurrent low grade glioma
Do you have a low grade glioma brain tumor that has come back after your initial diagnosis? If so, you might be eligible to enroll in OPTIMUM—a study of people with recurrent low grade glioma in the United States. Recurrent means a tumor has come back after an initial diagnosis.

The Low Grade Glioma Registry & OPTIMUM are headed by Elizabeth B. Claus, MD, PhD, of Yale School of Public Health and Brigham & Women’s Hospital, funded by the National Cancer Institute (NCI) and NCI Cancer Moonshot℠.